Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage. / Bejder, Jacob; Aachmann-Andersen, Niels Jacob; Bonne, Thomas Christian; Olsen, Niels Vidiendal; Nordsborg, Nikolai Baastrup.
In: Drug Testing and Analysis, Vol. 8, No. 10, 10.2016, p. 1049-1055.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage
AU - Bejder, Jacob
AU - Aachmann-Andersen, Niels Jacob
AU - Bonne, Thomas Christian
AU - Olsen, Niels Vidiendal
AU - Nordsborg, Nikolai Baastrup
N1 - CURIS 2016 NEXS 276
PY - 2016/10
Y1 - 2016/10
N2 - The sensitivity of the adaptive model of the Athlete Biological Passport (ABP) and reticulocyte percentage (ret%) in detection of recombinant human erythropoietin (rHuEPO) misuse was evaluated using both a long-term normal dose and a brief high dose treatment regime. Sixteen subjects received either 65IU rHuEPO×kg-1 every second day for two weeks (normal-dose), 390IU rHuEPO×kg-1 on three consecutive days (high-dose), or frequent placebo treatment for 13days in a randomized, placebo-controlled, double-blind crossover design. Blood variables were measured 4, 11, and 25days following treatment initiation. The ABP based on haemoglobin concentration ([Hb]) and OFF-hr score ([Hb] - 60×√ret%) yielded atypical profiles following both normal-dose and high-dose treatment (0 %, 31 %, 13 % vs. 21 %, 33 %, 20 % at days 4, 11, and 25 after normal and high dose, respectively). Including ret% as a stand-alone marker for atypical blood profiles increased (P<0.05) the sensitivity of the adaptive model at day 11 to 63 % and 67 % for normal-dose and high-dose rHuEPO administration, respectively. In conclusion, ~30 % of subjects injecting a normal-dose rHuEPO for two weeks or a high-dose rHuEPO for three days will present an atypical ABP profile. Including ret% as a stand-alone parameter improves the sensitivity two-fold.
AB - The sensitivity of the adaptive model of the Athlete Biological Passport (ABP) and reticulocyte percentage (ret%) in detection of recombinant human erythropoietin (rHuEPO) misuse was evaluated using both a long-term normal dose and a brief high dose treatment regime. Sixteen subjects received either 65IU rHuEPO×kg-1 every second day for two weeks (normal-dose), 390IU rHuEPO×kg-1 on three consecutive days (high-dose), or frequent placebo treatment for 13days in a randomized, placebo-controlled, double-blind crossover design. Blood variables were measured 4, 11, and 25days following treatment initiation. The ABP based on haemoglobin concentration ([Hb]) and OFF-hr score ([Hb] - 60×√ret%) yielded atypical profiles following both normal-dose and high-dose treatment (0 %, 31 %, 13 % vs. 21 %, 33 %, 20 % at days 4, 11, and 25 after normal and high dose, respectively). Including ret% as a stand-alone marker for atypical blood profiles increased (P<0.05) the sensitivity of the adaptive model at day 11 to 63 % and 67 % for normal-dose and high-dose rHuEPO administration, respectively. In conclusion, ~30 % of subjects injecting a normal-dose rHuEPO for two weeks or a high-dose rHuEPO for three days will present an atypical ABP profile. Including ret% as a stand-alone parameter improves the sensitivity two-fold.
KW - Blood manipulation
KW - Doping control
KW - Recombinant human erythropoietin
U2 - 10.1002/dta.1932
DO - 10.1002/dta.1932
M3 - Journal article
C2 - 27696774
AN - SCOPUS:84952361635
VL - 8
SP - 1049
EP - 1055
JO - Drug Testing and Analysis
JF - Drug Testing and Analysis
SN - 1942-7603
IS - 10
ER -
ID: 166460499